Table 2.

Proportion of patients free of individual NEDA-3 components over 5 years (modified efficacy analysis set)

NEDA-3 components	OMB-OMB N = 843 n/M (%)		TER-OMBa N = 855 n/M (%)
Patients free of Gd+ T1 lesions	796/820 (97.1)	542/839 (64.6)
Patients free of neT2 lesions	391/820 (47.7)		211/839 (25.1)
Patients free of confirmed relapses	620/820 (75.6)		530/839 (63.2)
Patients free of 6mCDW	680/820 (82.9)		677/839 (80.7)

Data are from the modified efficacy analysis set for NEDA-3

6mCDW 6-month confirmed disability worsening; Gd+ gadolinium-enhancing; NEDA-3 three parameter no evidence of disease activity; neT2 new or enlarging T2; OMB-OMB continuous ofatumumab; TER-OMB switch from teriflunomide to ofatumumab

^aPatients who completed treatment with teriflunomide in the core period were switched to ofatumumab in the open-label extension period